DaVita Inc. with ticker code (DVA) have now 9 market analysts covering the stock. The analyst consensus now points to a rating of ‘none’. The range between the high target price and low target price is between $186.00 and $134.00 and has a mean share price target at $156.90. (at the time of writing). Now with the previous closing price of $167.96 this indicates there is a potential downside of -6.6%. The 50 day moving average now sits at $158.47 and the 200 day MA is $144.13. The company has a market cap of 13.59B. The stock price is currently at: $165.63 USD
The potential market cap would be $12,691,214,236 based on the market consensus.
The company has a dividend yield of 3.8%. Other points of data to note are a P/E ratio of 17.85, revenue per share of $145.29 and a 6.94% return on assets.
DaVita Inc. is a healthcare provider. The Company provides kidney care services in the United States. The Company’s operations are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (its ancillary services). The U.S. dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, and end-stage kidney disease (ESKD). Its services include outpatient hemodialysis services, hospital inpatient hemodialysis services, and home-based dialysis services. The ancillary services consist of integrated kidney care services, physician services, clinical research programs, and transplant software business, as well as international operations. The Company operates approximately 2,724 outpatient dialysis centers in the United States.
